scholarly journals Multiplexed Protease Activity Assay for Low-Volume Clinical Samples Using Droplet-Based Microfluidics and Its Application to Endometriosis

2012 ◽  
Vol 135 (5) ◽  
pp. 1645-1648 ◽  
Author(s):  
Chia-Hung Chen ◽  
Miles A. Miller ◽  
Aniruddh Sarkar ◽  
Michael T. Beste ◽  
Keith B. Isaacson ◽  
...  
Keyword(s):  
Protease Activity ◽  
Clinical Samples ◽  
Activity Assay ◽  
Low Volume

Azocoll protease activity assay

2007 ◽  
Author(s):  
Naxin Jiang ◽  
Nguan Soon Tan ◽  
Bow Ho ◽  
Jeak Ling Ding
Keyword(s):  
Protease Activity ◽  
Activity Assay

Chronoamperometric Biosensor for Protease Activity Assay and Inhibitor Screening

2017 ◽  
Vol 29 (10) ◽  
pp. 2395-2400 ◽  
Author(s):  
Loubna El Harrad ◽  
Aziz Amine
Keyword(s):  
Protease Activity ◽  
Activity Assay ◽  
Inhibitor Screening

scholarly journals A new two-mode fluorescence signal amplification strategy for protease activity assay based on graphene oxide

RSC Advances ◽  
2017 ◽  
Vol 7 (76) ◽  
pp. 47983-47989 ◽  
Author(s):  
Fangfang Wang ◽  
Jie Gao ◽  
Jianwei Zhao ◽  
Wenyue Zhang ◽  
Jie Bai ◽  
...  
Keyword(s):  
Graphene Oxide ◽  
Signal Amplification ◽  
Protease Activity ◽  
Fluorescence Signal ◽  
Activity Assay ◽  
Fluorescence Signal Amplification ◽  
Amplification Strategy

A new graphene oxide-based two-mode fluorescence signal amplification strategy for the detection of protease activity has been established.

A colorimetric protease activity assay method using engineered procaspase-3 enzymes

2016 ◽  
Vol 8 (33) ◽  
pp. 6270-6276 ◽  
Author(s):  
Dokyung Yang ◽  
Hyeon Ji Park ◽  
Tae Hyeon Yoo
Keyword(s):  
Protease Activity ◽  
Assay Method ◽  
Activity Assay ◽  
Platform Technology ◽  
Protease Assay ◽  
Diagnosis Of Diseases

A protease assay platform technology based on engineered proenzymes has been developed for diagnosis of diseases.

Clinical Use of a Rapid Collagen Binding Assay for von Willebrand Factor Cleaving Protease in Patients with Thrombotic Thrombocytopenic Purpura

2002 ◽  
Vol 88 (10) ◽  
pp. 598-604 ◽  
Author(s):  
Stephan Moll ◽  
Mark Taylor ◽  
Dennis Krizek ◽  
Gilbert White ◽  
David Aronson ◽  
...  
Keyword(s):  
Von Willebrand Factor ◽  
Predictive Value ◽  
Protease Activity ◽  
Binding Assay ◽  
Clinical Syndrome ◽  
Clinical Samples ◽  
Activity Levels ◽  
Collagen Binding ◽  
Von Willebrand ◽  
Willebrand Factor

SummaryA simple collagen binding assay (CBA) for measuring activity of the von Willebrand factor cleaving protease in clinical samples is described, and results of fifty masked plasmapheresis samples from patients with TTP/HUS and other diseases are presented.There was 97.5% concordance between the CBA and a multimer gel assay. The CBA identified low protease activity in 78% of patients who had a clinical syndrome consistent with TTP/HUS and in 2 of 10 sick controls, giving it a positive predictive value of 0.94. The heterogeneity regarding the presence or absence of vWF protease activity in patients with TTP/HUS was confirmed by finding a low negative predictive value of 0.50 with the CBA. The CBA detected inhibitors of the protease in 26 of 29 patients (90%) with TTP/HUS and low protease activity levels. The CBA is a useful clinical assay for examining von Willebrand factor protease activity and detecting inhibitors against the protease.

scholarly journals Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies

Pharmaceutics ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1390
Author(s):  
Bruce Howng ◽  
Michael B. Winter ◽  
Carol LePage ◽  
Irina Popova ◽  
Michael Krimm ◽  
...  
Keyword(s):  
Protease Activity ◽  
Ex Vivo ◽  
Human Tumor ◽  
Cancer Therapeutics ◽  
Biological Tissues ◽  
Clinical Samples ◽  
Reliable Technique ◽  
Physiological Processes ◽  
Wide Range ◽  
Therapeutic Development

Proteases are involved in the control of numerous physiological processes, and their dysregulation has been identified in a wide range of pathologies, including cancer. Protease activity is normally tightly regulated post-translationally and therefore cannot be accurately estimated based on mRNA or protein expression alone. While several types of zymography approaches to estimate protease activity exist, there remains a need for a robust and reliable technique to measure protease activity in biological tissues. We present a novel quantitative ex vivo zymography (QZ) technology based on Probody® therapeutics (Pb-Tx), a novel class of protease-activated cancer therapeutics that contain a substrate linker cleavable by tumor-associated proteases. This approach enables the measurement and comparison of protease activity in biological tissues via the detection of Pb-Tx activation. By exploiting substrate specificity and selectivity, cataloguing and differentiating protease activities is possible, with further refinement achieved using protease-specific inhibitors. Using the QZ assay and human tumor xenografts, patient tumor tissues, and patient plasma, we characterized protease activity in preclinical and clinical samples. The QZ assay offers the potential to increase our understanding of protease activity in tissues and inform diagnostic and therapeutic development for diseases, such as cancer, that are characterized by dysregulated proteolysis.

scholarly journals Protease Activity Assay in Fly Intestines

BIO-PROTOCOL ◽  
2017 ◽  
Vol 7 (18) ◽  
Author(s):  
Marie-Paule Nawrot-Esposito ◽  
Rihab Loudhaief ◽  
Armel Gallet
Keyword(s):  
Protease Activity ◽  
Activity Assay
Sign in / Sign up

Export Citation Format

Share Document